1h Free Analyst Time
Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France.Sanofi Key Recent Developments
- Apr 17, 2023: Elisabeth Moreno to join Sanofi's Diversity, Equity and Inclusion Board
- Apr 10, 2023: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio
- Apr 04, 2023: Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
- Mar 02, 2023: Sanofi launches R&D Consortium of industry and patient advocacy groups to accelerate medicines development
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Receptos Inc
- Novartis AG
- Lumos Pharma Inc
- Heska Corp
- Pfizer Inc
- Novo Nordisk AS
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Co
- Bristol-Myers Squibb Co
- Merck & Co Inc
- Johnson & Johnson
- Boehringer Ingelheim International GmbH
- Bayer AG
- Qiagen Marseille SA
- Indivior Plc
- GSK plc
- Amgen Inc
- Innocoll Holdings Ltd
- Groupe SOLACTIS SAS
- AstraZeneca Plc
- Correvio Pharma Corp
- Boehringer Ingelheim International GmbH
- Receptos Inc
- Novartis AG
- Lumos Pharma Inc
- Generex Biotechnology Corp
- Pfizer Inc
- F. Hoffmann-La Roche Ltd
- Correvio Pharma Corp
- AstraZeneca Plc
- Qiagen Marseille SA
- Indivior Plc
- GSK plc
- AnaptysBio Inc
- Merck & Co Inc
- Johnson & Johnson
- Bayer AG
- Heska Corp
- Innocoll Holdings Ltd
- Groupe SOLACTIS SAS
- Novo Nordisk AS
- Eli Lilly and Co
- Bristol-Myers Squibb Co